Sorrento Therapeutics focuses on developing antibody-based therapies, a prominent approach in modern biopharmaceuticals that utilizes the immune system's ability to identify and neutralize harmful substances.
The company originally founded in 2006 pursued a variety of therapeutic areas but has recently honed in on oncology, infectious diseases, and pain management, marking a significant focus shift in their drug development strategy.
Also worth reading: How does PCCT lung nodule AI integration improve diagnostic accuracy and workflow efficiency in modern radiology departments? · How does photon counting CT lung cancer screening compare to conventional CT for early detection and patient safety? · What are the definitive HSA vs FSA tax differences for 2026?
One notable innovation from Sorrento is its proprietary G-MAB technology platform, which enables the rapid generation of fully human monoclonal antibodies, designed to improve efficacy while minimizing potential side effects.
Sorrento’s approach to pain management includes developing non-opioid treatments, addressing the critical need for alternatives in a landscape plagued by opioid dependency crises.
The company also has a solid portfolio of COVID-19 related therapies, focusing on neutralizing antibodies that can potentially limit the severity of coronavirus infections.
In February 2023, Sorrento filed for Chapter 11 bankruptcy protection, revealing struggles with debt and complex legal disputes, which can significantly impact ongoing clinical trials and product availability.
During its restructuring, the company indicated plans to focus on a more streamlined set of core therapeutic assets, potentially enhancing their overall product development pipeline.
Sorrento has faced competition and contract disputes, like those with NantCell regarding patent rights for specific treatments, which illustrate the highly competitive nature of the biopharma industry.
Their experimental therapies utilize advanced techniques such as CAR-T cell therapy, which modifies a patient’s own immune cells to better target and destroy cancer cells.
Some of Sorrento’s investigational therapies are being evaluated for their ability to treat chronic pain using mechanisms different from traditional analgesics, emphasizing the role of new biological pathways.
Sorrento has partnerships with other biopharmaceutical entities, leveraging technology and knowledge-sharing that can accelerate the development and regulatory pathways of its products.
Recently, Sorrento announced advancements in their immune-oncology pipeline which looks at using engineered immune cells to combat particularly resilient cancer types, showcasing the trend of integrating immunotherapy into cancer care.
The FDA’s expedited review mechanisms have been leveraged by Sorrento for some of its therapies, illustrating the agency’s commitment to fast-tracking promising treatments in response to urgent health needs.
As of late 2023, Sorrento has reported advancements in their efforts using Intravenous delivery methods for certain therapies, which can increase bioavailability, leading to more effective treatment outcomes.
Sorrento’s research includes examining the potential use of peptides derived from venomous species as a unique approach to target cancer cells, representing an innovative avenue in drug discovery.
The company operates on a global scale, often conducting clinical trials in various regions to broaden the demographic reach and include diverse genetic populations for more comprehensive data.
Sorrento’s use of pharmacogenomics, the study of how genes affect a person’s response to drugs, underscores their commitment to personalized medicine, tailoring therapies based on individual genetic profiles.
The ongoing legal battles surrounding some of their drug rights could significantly affect timelines for FDA approvals and market entry, a challenging aspect of their operational framework.
Sorrento has been working on treatments to manage COVID-19 variants, showcasing the dynamic landscape of infectious disease research as new viral strains continue to emerge.
The technological innovations pursued by Sorrento in drug development, such as AI-driven drug discovery platforms, reflect a growing trend of integrating computational tools in the pharmaceutical research process.